Soap siren talks atrial fibrilation for Boehringer Ingelheim awareness effort

Share this article:
Soap siren talks atrial fibrilation for Boehringer Ingelheim awareness effort
Soap siren talks atrial fibrilation for Boehringer Ingelheim awareness effort
Soap star Susan Lucci is fronting an awareness campaign by Boehringer Ingelheim promoting awareness of atrial fibrillation.

Lucci's husband Helmut Huber, who appears in the unbranded campaign, is one of an estimated 2.3 million Americans who suffer the condition, an irregular heartbeat which can increase the risk of stroke nearly five-fold. Earlier this week, Boehringer Ingelheim's anticoagulant Pradaxa (dabigatran etexilate) won the unanimous assent of an FDA advisory committee for stroke prevention in patients with atrial fibrillation.

The company is partnering with the National Stroke Association and StopAfib.org on the effort, a multi-year education program aimed at raising awareness of the condition and facilitating better dialogue between patients and physicians grappling with the condition. It includes a website, www.FacingAFib.com, through which patients can order a free book on the disease, associated with 15% of strokes in the US, and register for program updates.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...